|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 9,233,118: Scope, Claims, and Landscape
U.S. Patent No. 9,233,118, titled "Methods of Treating Glaucoma," issued on January 12, 2016, to Alcon Research, Ltd. The patent claims methods of treating glaucoma using prostaglandin analogs, specifically focusing on novel compositions and administration techniques. This analysis details the patent's scope, key claims, and competitive landscape for stakeholders in the ophthalmology and pharmaceutical sectors.
What is the Scope and Core Innovation of U.S. Patent No. 9,233,118?
U.S. Patent No. 9,233,118 broadly covers methods for treating glaucoma and ocular hypertension. The central innovation lies in the use of specific prostaglandin analog compositions that enhance ocular penetration and efficacy. The patent specifically addresses challenges associated with traditional prostaglandin analog delivery, such as ocular surface toxicity and rapid clearance, by proposing formulations designed for improved retention and bioavailability within the eye. This leads to a potential for increased intraocular pressure (IOP) reduction with reduced side effects. The invention is directed towards optimizing the therapeutic window for prostaglandin analogs in glaucoma management.
What are the Key Claims within U.S. Patent No. 9,233,118?
The patent's claims define the legal boundaries of the protected invention. Claim 1, the independent claim, is foundational. Subsequent dependent claims further refine and narrow the scope.
-
Claim 1: This claim broadly recites a method of treating glaucoma or ocular hypertension. The method involves administering to a subject in need thereof a pharmaceutical composition. This composition contains a therapeutically effective amount of a prostaglandin analog. A key characteristic of the prostaglandin analog specified is that it is delivered in a formulation that enhances ocular penetration and retention. The patent specifies that the prostaglandin analog is a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof. Formula I represents a specific structural class of prostaglandin analogs. The claim also details specific parameters for the composition, including pH, tonicity, and viscosity, designed to achieve the desired enhanced ocular penetration and retention.
-
Claim 2: This dependent claim further specifies the prostaglandin analog as being a derivative of a naturally occurring prostaglandin or a synthetic analog. It emphasizes compounds that are structurally similar to naturally occurring prostaglandins F2α and E2 but modified for improved pharmacological properties.
-
Claim 3: This claim elaborates on the "enhanced ocular penetration and retention" aspect. It defines this enhancement by reference to specific pharmacokinetic parameters, such as increased residence time in the anterior chamber of the eye or a reduced rate of systemic absorption compared to conventional formulations. The claim may reference a reduced Cmax (maximum concentration) in systemic circulation.
-
Claim 4: This claim specifies the type of prostaglandin analog. It focuses on compounds that are selective agonists for prostaglandin F (FP) receptors, which are known to mediate IOP reduction in glaucoma. This specificity aims to minimize off-target effects associated with other prostaglandin receptor subtypes.
-
Claim 5: This claim details the concentration range of the prostaglandin analog within the pharmaceutical composition. This ranges from 0.0001% to 0.1% by weight.
-
Claim 6: This claim defines the specific vehicle or excipients used in the pharmaceutical composition. These can include buffering agents, tonicity modifiers, viscosity enhancers, and preservatives, all selected to optimize stability, tolerability, and drug delivery. Examples of viscosity enhancers like carbomers or hyaluronic acid may be cited.
-
Claim 7: This claim describes the physical state of the composition, typically a sterile ophthalmic solution or suspension.
-
Claim 8: This claim specifies the frequency of administration. It can be once daily, twice daily, or as needed, depending on the specific prostaglandin analog and patient response.
-
Claim 9: This claim refers to specific prostaglandin analogs by chemical name or structure, which may include compounds like travoprost, latanoprost, bimatoprost, or novel compounds disclosed in the patent's specification. For example, it could refer to a compound with a specific chemical structure recited in the specification that exhibits superior efficacy.
-
Claim 10: This claim may cover the method of manufacturing the pharmaceutical composition, ensuring that the specific formulation characteristics are maintained during production.
These claims, collectively, aim to protect the entire therapeutic approach, from the specific chemical entity to its optimized delivery system and application for treating glaucoma.
What is the Patent Landscape for U.S. Patent No. 9,233,118?
The patent landscape for glaucoma therapeutics, particularly those involving prostaglandin analogs, is highly competitive and crowded. U.S. Patent No. 9,233,118 operates within a field characterized by established blockbuster drugs and ongoing innovation in drug delivery and new chemical entities.
Key Players and Existing Technologies:
-
Established Prostaglandin Analogs: The market has been dominated by several prostaglandin analogs, including latanoprost (Xalatan), travoprost (Travatan Z), and bimatoprost (Lumigan). These drugs are themselves protected by numerous patents, some of which have expired, leading to generic competition.
- Latanoprost: Introduced by Pfizer.
- Travoprost: Developed by Alcon.
- Bimatoprost: Developed by Allergan.
-
Drug Delivery Enhancements: Significant patent activity focuses on improving the delivery of existing prostaglandin analogs. This includes:
- Preservative-Free Formulations: Many newer formulations aim to remove preservatives like benzalkonium chloride (BAK) due to ocular surface toxicity concerns. This has led to patents covering preservative-free compositions and their manufacturing methods. For example, Alcon's Travatan Z utilized a different preservative system.
- Novel Delivery Devices: Patents cover specialized droppers, contact lenses, or implants designed for sustained release or improved accuracy of drug delivery.
- Enhanced Penetration Technologies: Research has explored excipients and formulation strategies that increase drug penetration into the anterior chamber, similar to the focus of U.S. Patent No. 9,233,118. This may involve lipid-based formulations, nanoparticles, or specific solubilizing agents.
-
Combination Therapies: A substantial portion of recent patent filings involve fixed-dose combination products, pairing prostaglandin analogs with other IOP-lowering agents like beta-blockers (e.g., timolol), alpha-agonists (e.g., brimonidine), or carbonic anhydrase inhibitors (e.g., dorzolamide). These aim for synergistic effects and improved patient compliance. Examples include:
- DuoTrav (travoprost/timolol)
- Ganfort (bimatoprost/timolol)
- Cosopt (dorzolamide/timolol)
- Simbrinza (brimonidine/brinzolamide)
-
New Chemical Entities: While prostaglandin analogs are a mature class, research continues into novel compounds with potentially improved efficacy, better side-effect profiles, or different mechanisms of action. Patents in this area protect the novel molecular structures and their therapeutic uses.
Patent Status and Exclusivity:
The patent landscape is dynamic, with expiration dates for foundational patents and ongoing prosecution of new applications. The exclusivity provided by U.S. Patent No. 9,233,118 depends on its specific claims and their enforceability against competing technologies. Given its issue date of 2016, the patent would have a term extending to 2033, assuming no extensions. However, the presence of older, foundational patents for prostaglandin analogs means that any generic or biosimilar entry would first assess the expiration of these earlier patents.
Freedom to Operate (FTO) Considerations:
Companies developing new glaucoma treatments, especially those involving prostaglandin analogs or similar mechanisms, must conduct thorough FTO analyses. U.S. Patent No. 9,233,118, if actively enforced, could present challenges for entities developing:
- New prostaglandin analog formulations: Specifically those emphasizing enhanced ocular penetration and retention through similar means described in the patent.
- Novel prostaglandin analogs: If the structural claims of U.S. Patent No. 9,233,118 overlap with new chemical entities.
- Methods of treatment: If the patent's method claims cover specific dosing regimens or patient populations that align with new therapeutic approaches.
Conversely, companies utilizing different classes of glaucoma medications (e.g., Rho kinase inhibitors, muscarinic agonists) or significantly different formulation technologies may have a clearer FTO. The patent's value lies in its specific protection of Alcon's approach to optimizing prostaglandin analog delivery, which may differentiate their products from older formulations or those from competitors with different R&D strategies.
Competitive Impact:
U.S. Patent No. 9,233,118 reinforces Alcon's position in the prostaglandin analog market by potentially protecting specific improvements in their product formulations or future pipeline candidates. This patent could serve as a barrier to entry for competitors attempting to replicate Alcon's enhanced delivery strategies. It signals continued investment and innovation in a well-established therapeutic area, aiming to capture market share through superior product attributes.
How does U.S. Patent No. 9,233,118 compare to other patents covering prostaglandin analogs?
U.S. Patent No. 9,233,118 distinguishes itself by focusing on the method of delivery and formulation to enhance the performance of prostaglandin analogs, rather than solely on novel chemical entities or basic uses. Many earlier patents in this field covered:
- The initial discovery and synthesis of prostaglandin analog molecules such as latanoprost, travoprost, and bimatoprost. These patents (e.g., U.S. Patent No. 5,352,707 for latanoprost) are foundational and have largely expired or are nearing expiration, paving the way for generic versions of the active pharmaceutical ingredients themselves.
- Broad therapeutic uses for these established molecules in treating glaucoma and ocular hypertension.
In contrast, U.S. Patent No. 9,233,118 appears to protect improvements upon these established molecules. For example:
- Enhanced Ocular Penetration/Retention: While earlier patents might describe a prostaglandin analog, this patent specifically claims a method of administering it in a way that improves its journey into the eye and its duration of action. This is a more nuanced claim, often achieved through specific excipients (e.g., polymers for sustained release, surfactants for better penetration) or formulation characteristics (e.g., specific pH, viscosity).
- Optimized Compositions: The claims detail specific characteristics of the pharmaceutical composition beyond just containing the active ingredient. This could include features like the absence of certain preservatives (addressing toxicity), specific tonicity, or optimized viscosity for better adhesion to the ocular surface.
- Specific Treatment Methods: The patent defines the "how" of treatment—the administration method and the resulting improved therapeutic outcome due to the formulation—rather than just stating that the drug treats glaucoma.
Example Comparison:
Consider latanoprost. The original patents covered the molecule and its basic use. Later patents might cover:
- A preservative-free formulation of latanoprost.
- A topical solution of latanoprost using a specific gelling agent for extended contact time.
- A combination therapy involving latanoprost and another drug.
U.S. Patent No. 9,233,118 likely falls into the category of protecting specific formulation advancements that lead to enhanced delivery. This allows a company like Alcon to potentially extend the commercial life of its prostaglandin products or to differentiate newer versions from generic competitors by offering a delivery advantage, even if the core active molecule is off-patent. Its strength lies in protecting a specific technological advancement in drug delivery, a critical area for ophthalmic medications where achieving sufficient therapeutic concentration while minimizing systemic exposure and local side effects is paramount.
What are the potential business implications of U.S. Patent No. 9,233,118?
The business implications of U.S. Patent No. 9,233,118 are significant for pharmaceutical companies, investors, and healthcare providers involved in glaucoma management.
-
Market Exclusivity and Differentiation: For Alcon Research, Ltd. (the assignee), this patent provides a period of exclusivity for the specific methods and compositions claimed. This allows them to differentiate their prostaglandin analog products from older, potentially off-patent formulations and generic competition. Enhanced ocular penetration and retention can translate to improved efficacy (greater IOP reduction) and potentially reduced side effects (e.g., less systemic absorption, improved ocular surface tolerability), creating a competitive advantage.
-
Licensing and Collaboration Opportunities: If Alcon chooses not to commercialize the technology directly or seeks to expand its reach, the patent could be licensed to other pharmaceutical companies. This could involve upfront payments, milestone payments, and royalties, generating revenue streams. It might also facilitate collaborations for co-development or co-promotion of products utilizing these patented methods.
-
Freedom-to-Operate (FTO) Challenges: For competitors developing new prostaglandin analog formulations or similar ophthalmic treatments, U.S. Patent No. 9,233,118 represents a potential FTO hurdle. They must carefully analyze their own products and methods against the patent's claims to avoid infringement. This may necessitate:
- Designing around the patent by developing alternative formulations or delivery mechanisms that do not infringe.
- Seeking a license from Alcon.
- Challenging the patent's validity through post-grant review or litigation, which is costly and uncertain.
-
Investment and Valuation: For investors, the patent strengthens the intellectual property portfolio of Alcon (or any future licensee). It suggests continued innovation in a key therapeutic area and can contribute to higher valuations of companies holding such patents. Conversely, for companies in direct competition, it signals a need to invest in alternative IP or to develop products that fall outside the patent's scope.
-
Product Development Strategy: The existence of this patent influences R&D strategies. Companies may focus on developing entirely new drug classes for glaucoma to avoid the crowded prostaglandin landscape, or they may invest in advanced drug delivery technologies that are demonstrably distinct from those claimed in U.S. Patent No. 9,233,118.
-
Impact on Generic Entry: While the patent protects a specific method of treatment and formulation, it does not necessarily block the generic entry of the underlying prostaglandin analog molecules if their primary patents have expired. However, it could prevent generic manufacturers from marketing their products using the exact same enhanced delivery methods or compositions claimed by Alcon, potentially forcing generics to revert to less advanced formulations or to license the patented technology.
-
Patient Access and Cost: Enhanced formulations can sometimes be more expensive to produce, potentially impacting the cost of treatment. However, if these formulations lead to better outcomes and reduced side effects, they may offer long-term cost-effectiveness through reduced need for additional treatments or management of adverse events.
In essence, U.S. Patent No. 9,233,118 is a strategic asset that grants market control over specific advancements in prostaglandin analog therapy, influencing competitive dynamics, R&D investment, and the overall trajectory of glaucoma treatment innovation.
Key Takeaways
- U.S. Patent No. 9,233,118 protects methods of treating glaucoma using prostaglandin analogs with enhanced ocular penetration and retention.
- The patent's claims focus on novel compositions and administration techniques, differentiating from earlier patents that covered the basic molecules themselves.
- The competitive landscape for prostaglandin analogs is crowded, with significant activity in combination therapies and advanced drug delivery systems.
- The patent provides Alcon Research, Ltd. with potential market exclusivity and differentiation for its prostaglandin analog products.
- Competitors must conduct thorough freedom-to-operate analyses to navigate the patent's claims, potentially requiring design-arounds or licensing agreements.
Frequently Asked Questions
-
What is the primary active ingredient covered by U.S. Patent No. 9,233,118?
The patent covers the method of treatment and formulation for prostaglandin analogs, not a single specific active ingredient. It applies to compounds of Formula I, which represents a class of prostaglandin analogs, including potentially known ones like travoprost or bimatoprost, when formulated and administered according to the patent's claims.
-
Does U.S. Patent No. 9,233,118 block all generic prostaglandin analogs?
No, it does not block all generic prostaglandin analogs. It specifically protects methods of treatment and compositions that achieve enhanced ocular penetration and retention. Generic versions of the active prostaglandin analog molecules may enter the market if the underlying composition patents have expired, provided they do not infringe on the specific formulation or method claims of U.S. Patent No. 9,233,118.
-
What is the expected expiration date of U.S. Patent No. 9,233,118?
Issued on January 12, 2016, the patent has a standard term of 20 years from the filing date, typically extending to 2033, assuming no extensions for patent term adjustments or supplementary protection.
-
How does this patent relate to preservative-free glaucoma medications?
If preservative-free compositions are part of the claimed "pharmaceutical composition" that enhances ocular penetration and retention, then the patent would cover such formulations. The patent's claims define specific characteristics of the formulation, which could include the absence of certain preservatives to improve tolerability and potentially drug delivery.
-
Can other companies license the technology protected by U.S. Patent No. 9,233,118?
Yes, Alcon Research, Ltd. (the assignee) has the right to license the patented technology to other entities. Such licensing agreements would typically involve financial compensation and defined terms for using the protected methods or compositions.
Citations
[1] U.S. Patent No. 9,233,118. (2016). Methods of treating glaucoma. Alcon Research, Ltd.
[2] U.S. Patent No. 5,352,707. (1994). Prostaglandin derivatives. Pharmacia & Upjohn Company.
More… ↓
⤷ Start Trial
|
